Climb Bio (NASDAQ:CLYM) Issues Quarterly Earnings Results

Key Points

• Climb Bio reported a quarterly loss of $0.18 per share, beating the consensus estimate of a $0.20 loss by $0.02.
• Shares fell $0.46 to $8.87 during Thursday’s midday trading, despite the earnings beat.
• Analysts’ consensus rating is “Buy,” with an average price target of $28.14; ratings include two Strong Buys, twelve Buys and one Sell.

Climb Bio (NASDAQ:CLYM - Get Free Report) issued its earnings results on Thursday. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.02, FiscalAI reports.

Climb Bio Stock Performance

Climb Bio stock traded down $0.46 during midday trading on Thursday, hitting $8.87. 1,435,453 shares of the company's stock were exchanged, compared to its average volume of 1,173,261. The company has a market cap of $509.49 million, a P/E ratio of -10.69 and a beta of 0.01. The stock has a 50-day moving average price of $12.00 and a two-hundred day moving average price of $10.44. Climb Bio has a 52-week low of $1.63 and a 52-week high of $18.33.

Insider Buying and Selling at Climb Bio

In other Climb Bio news, Director Stephen Thomas sold 100,000 shares of the firm's stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $13.67, for a total value of $1,367,000.00. Following the sale, the director owned 467,969 shares of the company's stock, valued at $6,397,136.23. This trade represents a 17.61% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 2.60% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Climb Bio from a "hold" rating to a "sell" rating in a report on Saturday, October 3rd. HC Wainwright reaffirmed a "buy" rating on shares of Climb Bio in a research note on Monday, October 12th. Deutsche Bank Aktiengesellschaft began coverage on shares of Climb Bio in a report on Tuesday, October 20th. They set a "buy" rating and a $28.00 target price on the stock. BTIG Research reiterated a "buy" rating and issued a $32.00 target price on shares of Climb Bio in a research note on Tuesday, October 27th. Finally, B. Riley Financial reiterated a "buy" rating on shares of Climb Bio in a research note on Friday, September 4th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $28.14.

About Climb Bio

Climb Bio, Inc NASDAQ: CLYM is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. The company is working to create medicines that target B cells, which play a central role in the immune responses associated with many autoimmune disorders.

Climb Bio's lead investigational product, CLYM116, is a fully human anti-CD19 monoclonal antibody designed to selectively deplete B cells. The therapy is being evaluated in clinical development for autoimmune conditions, including primary membranous nephropathy, a kidney disorder in which abnormal immune activity can damage the kidneys.

As a development-stage biotechnology company, Climb Bio's activities are centered on research, clinical trials and the potential commercialization of its pipeline rather than on marketed products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.